- Home
- DSM vs PALI Comparison
DSM vs PALI Comparison
Compare DSM & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$1.87
Company Overview
Basic Information| Metric | DSM | PALI |
|---|---|---|
| Founded | 1989 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 306.0M | 333.6M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | DSM | PALI |
|---|---|---|
| Price | $5.99 | $1.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $11.29 |
| AVG Volume (30 Days) | 79.6K | ★ 3.7M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 3.97% | N/A |
| EPS Growth | N/A | ★ 97.06 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $260,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1500.39 |
| 52 Week Low | $5.45 | $0.55 |
| 52 Week High | $6.30 | $2.86 |
Technical Indicators
Market Signals| Indicator | DSM | PALI |
|---|---|---|
| Relative Strength Index (RSI) | 42.68 | 46.53 |
| Support Level | $5.95 | $1.57 |
| Resistance Level | $6.22 | $1.93 |
| Average True Range (ATR) | 0.07 | 0.13 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 28.33 | 27.47 |
Price Performance
Historical Comparison DSM
PALI
About DSM BNY Mellon Strategic Municipal Bond Fund Inc.
BNY Mellon Strategic Municipal Bond Fund, Inc. is a diversified closed-end management investment company. Its investment objective is to seek to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital.
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.